RxDoctor Payments Data

Parvin Peddi

Internal Medicine · San Francisco, CANPI 1447346390

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Merck at 27.7% of the total. Reporting peaked in 2024 at $171 and has fallen 82.6% since, to $30 in 2025.

$293in general payments, 2019–2025

Across 12 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$81
  • Lilly USA, LLC$65
  • Daiichi Sankyo Inc.$55
  • Gilead$30
  • AstraZeneca$24
  • Immunogen, Inc.$22
  • plus $15 from 1 others
$498,172in research payments, 2019–2025

Across 19 payments — averaging $26,220 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$285K
  • Novartis$143K
  • Sanofi US Services Inc.$70K

What the payments were for

  • Food & beverage$293100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$293 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California →

Other internal medicine in San Francisco

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →